Dacoplice 30 mg Tablet

Description

Dacoplice 30 mg Tablet contains dacomitinib, a targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI). It is used in the treatment of certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations in the epidermal growth factor receptor (EGFR). By targeting abnormal signaling pathways involved in tumor growth, dacomitinib may help slow the progression of cancer when used as prescribed by a qualified healthcare professional. Dacomitinib works by blocking the activity of EGFR proteins that promote cancer cell growth and survival. In patients whose tumors carry EGFR-activating mutations, this targeted therapy may help control disease progression. Dacoplice tablets are taken orally and are generally part of a long-term treatment plan managed by an oncologist. Because targeted therapies can affect multiple biological pathways, patients receiving

Benefits

• Targets EGFR signaling, a key pathway involved in certain lung cancers

• Oral targeted therapy that can be taken at home under medical supervision

• Designed to inhibit multiple HER family receptors, potentially limiting tumor growth

• Used in patients with confirmed EGFR mutations

• Part of modern precision oncology treatment approaches

Indications and Usage

Dacoplice (dacomitinib) may be prescribed for:

• Metastatic non-small cell lung cancer (NSCLC)

• Patients whose tumors have EGFR exon 19 deletion or exon 21 L858R substitution mutations

• Treatment in adults with EGFR-mutated NSCLC confirmed by appropriate diagnostic testing

Use is determined by an oncologist based on genetic testing results and clinical evaluation.

How it Works

Dacomitinib works by inhibiting the epidermal growth factor receptor (EGFR) and other members of the HER family of receptors, which are proteins that help regulate cell growth and division. In certain lung cancers, mutations in the EGFR gene lead to uncontrolled activation of these signaling pathways, causing cancer cells to grow and spread.

By blocking these receptors, dacomitinib disrupts signals that promote tumor cell proliferation and survival. This targeted mechanism may help slow cancer progression in patients with EGFR-mutated tumors when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Dacoplice tablets are taken orally once daily, unless directed otherwise by a healthcare professional.

• Tablets should be swallowed whole with water.

• The medicine may be taken with or without food.

• Dose adjustments may be required depending on tolerance and side effects.

• Treatment duration is determined by the oncologist based on clinical response and disease progression.

Side Effects

Common side effects

• Diarrhea

• Skin rash or acne-like rash

• Mouth sores (stomatitis)

• Dry skin

• Decreased appetite

• Nail changes

Serious side effects

• Severe diarrhea leading to dehydration

• Lung inflammation (interstitial lung disease)

• Severe skin reactions

• Eye irritation or vision problems

• Liver function abnormalities

Patients should contact their healthcare provider if severe symptoms occur.

Warning and Precaution

• Risk of severe diarrhea and dehydration

• Possible interstitial lung disease or lung inflammation

• Skin reactions including rash or dermatitis

• Potential eye disorders such as keratitis

• Monitor liver function during treatment

• Pregnancy should be avoided during therapy

• Inform healthcare providers about all medicines and supplements before starting treatment

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend regular follow-up appointments and monitoring tests

• Report symptoms such as severe diarrhea, breathing difficulty, or skin reactions

• Inform your doctor about all medications and supplements you use

• Maintain proper hydration, especially if experiencing diarrhea

• Do not stop treatment without medical advice

Clinical Trial & Approvals

Dacomitinib has been evaluated in clinical trials for the treatment of EGFR-mutated non-small cell lung cancer. Studies such as the ARCHER 1050 trial demonstrated improved progression-free survival in certain patients compared with earlier therapies. Based on these results, dacomitinib has received regulatory approvals in several regions for the treatment of metastatic NSCLC with specific EGFR mutations.

References

• U.S. Food and Drug Administration (FDA) – Dacomitinib Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288lbl.pdf

• European Medicines Agency (EMA) – Dacomitinib Product Information
  https://www.ema.europa.eu

• National Cancer Institute – Dacomitinib Drug Information
  https://www.cancer.gov

• Drugs.com – Dacomitinib Drug Information
  https://www.drugs.com

• ClinicalTrials.gov – Studies Evaluating Dacomitinib
  https://clinicaltrials.gov

Prescription & documentation note

Dacoplice 30 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documents such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.